产品
编 号：F485682
分子式：C13H16N2
分子量：200.28
分子式：C13H16N2
分子量：200.28
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
447
In-stock
10mg
744
In-stock
50mg
3051
In-stock
结构图
CAS No: 86347-14-0
产品详情
生物活性：
Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels.
体内研究：
Medetomidine (200 μg/kg, p.o. or i.m.) induces a sedation in cats.Medetomidine (20 μg/kg, i.v.) shows sedative and analgesic effects in dogs.Medetomidine (0.05-0.3 mg/kg, s.c.) protects against Diazinon-induced toxicosis in mice.Animal Model:Diazinon (75 mg/kg, orally)-induced toxicosis in mice
Dosage:0.05, 0.1 and 0.3 mg/kg
Administration:Subcutaneous injection (s.c.), 15 min before Diazinon.
Result:Protected the mice from the toxicity induced by Diazinon.Decreased the occurrence of Straub tail, excessive salivation and tremor. Increased the latencies to onset of tremor and death when compared with control.
Animal Model:Dogs
Dosage:20 μg/kg
Administration:Intravenous injection (i.v.)
Result:Showed sedative and analgesic effects.Increased in SAP, MAP, DAP, MPAP, PCWP, CVP, SVR, PVR, core body temperature.Decreased in HR, CO, CI, SV, SI, RR, pH.
体外研究：
Medetomidine (0-1 μM, 1 h) inhibits aldosterone release from the adrenocortical cell suspension.Medetomidine (10 nM) activates a kicking response in Cyprids.Medetomidine (1 μM) increases cellular cAMP production by activating β-like receptors in CHO cells.
Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels.
体内研究：
Medetomidine (200 μg/kg, p.o. or i.m.) induces a sedation in cats.Medetomidine (20 μg/kg, i.v.) shows sedative and analgesic effects in dogs.Medetomidine (0.05-0.3 mg/kg, s.c.) protects against Diazinon-induced toxicosis in mice.Animal Model:Diazinon (75 mg/kg, orally)-induced toxicosis in mice
Dosage:0.05, 0.1 and 0.3 mg/kg
Administration:Subcutaneous injection (s.c.), 15 min before Diazinon.
Result:Protected the mice from the toxicity induced by Diazinon.Decreased the occurrence of Straub tail, excessive salivation and tremor. Increased the latencies to onset of tremor and death when compared with control.
Animal Model:Dogs
Dosage:20 μg/kg
Administration:Intravenous injection (i.v.)
Result:Showed sedative and analgesic effects.Increased in SAP, MAP, DAP, MPAP, PCWP, CVP, SVR, PVR, core body temperature.Decreased in HR, CO, CI, SV, SI, RR, pH.
体外研究：
Medetomidine (0-1 μM, 1 h) inhibits aldosterone release from the adrenocortical cell suspension.Medetomidine (10 nM) activates a kicking response in Cyprids.Medetomidine (1 μM) increases cellular cAMP production by activating β-like receptors in CHO cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备